Lexicon Pharmaceuticals, Inc. (LXRX)

NCM – Real Time Price. Currency in USD

2.55

+0.26 (11.35%)

At close: Jun 26, 2026, 4:00 PM EDT

2.56

+0.01 (0.37%)

After-hours: Jun 26, 2026, 7:57 PM EDT

11.06.2026

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Lexicon Pharmaceuticals focuses on precision medicines for chronic conditions, bolstered by significant revenue growth from its core drug programs. Pfizer remains a global giant with immense cash flow and a massive international footprint across hundreds of countries.

03.06.2026

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups

28.05.2026

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:00 p.m. ET in New York City.

12.05.2026

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on May 19, 2026.

08.05.2026

Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals NASDAQ: LXRX executives highlighted progress across late-stage regulatory programs and efforts to bolster the company's financial position during the company's first-quarter 2026 earnings call on May 7.

07.05.2026

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

07.05.2026

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon Pharmaceuticals (LXRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA ® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by Novo Nordisk Capital raise, development milestone payments, and recent $100 million loan facility reinforce strong financial position Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2026, and provided an update on key corporate milestones and accomplishments. “We have been intently focused on progressing our late and early-stage development pipeline in cardiometabolism and we are now well positioned to achieve several pivotal milestones as a result of those efforts,” said Mike Exton, Ph.D.

04.05.2026

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC) that provides up to $100 million in borrowing capacity. Access to this non-dilutive capital provides Lexicon with greater financial flexibility through both an extended interest-only period and maturity date and the opportunity to further strengthen its balance sheet to support pivotal upcoming regulatory and commercial milestones.

24.03.2026

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action

23.03.2026

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders

Lexicon Pharmaceuticals, Inc. (LXRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lexicon Pharmaceuticals, Inc. (LXRX)

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Videos

No Data

Press releases

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Videos

No Data

Press releases

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

Search stocks

Lexicon Pharmaceuticals, Inc. (LXRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lexicon Pharmaceuticals, Inc. (LXRX)

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Videos

No Data

Press releases

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Videos

No Data

Press releases

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851